Changes in plasma 5‐S-cysteinyldopa concentration in B16 melanoma‐bearing mice treated with interferon-β or dacarbazine
Changes in plasma 5‐S-cysteinyldopa concentration in B16 melanoma‐bearing mice treated with interferon-β or dacarbazine
复制标题
用干扰素-β或达卡巴嗪治疗的 B16 黑色素瘤小鼠血浆 5-S-半胱氨酰多巴浓度的变化
DOI：
10.1097/00008390-199310000-00013
复制
发表时间：
1993
影响因子：
2.2
通讯作者：
K. Ishihara
中科院分区：
文献类型：
--
作者：
K. Hasegawa;S. Inoue;K. Wakamatsu;S. Ito;K. Fujita;K. Ishihara
We have previously shown that the urinary excretion of 5-S-cysteinyldopa (5-S-CD) reflects well the progression of B16 mouse melanoma. We examined the usefulness of plasma concentration of 5-S-CD In following the progression of melanoma and evaluating the efficacy of immuno- and chemotherapeutic agents in the B16 mouse model. Murine lnterferon-β(MulNF-β; 3 × 105 U) or dacarbazine (DTIC; 50 mg/kg) was administered once a day for 10 or 5 consecutive days starting 8 days after subcutaneous Inoculation of B16 melanoma cells in C57BL/6 mice. Blood samples were collected from the tail vein and tumour volumes were measured every other day until day 24. Levels of 5-S-CD in plasma were determined by high-performance liquid chromatography. Tumours became palpable on day 6–8 and grew exponentially thereafter in the control mice. Tumours in INF-β-treated mice also grew exponentially, although at a reduced rate. However, the growth of tumours in the DTIC-treated mice was almost suppressed between days 12 and 18. Mean values of tumour volume on day 16 were 1.45, 1.05, and 0.83 cm3 in the control, INF-βMreated, and DTIC-treated groups, respectively. The plasma concentration of 5-S-CD began to Increase on day 8, at much slower rates in the experimental groups than those in the control group. Mean values of plasma 5-S-CD on day 16 were 14.3, 5.9, and 5.6 nmol/l in the control, INF-β-treated, and DTIC-treated groups; 5-S-CD level on day −2 was 1.8 nmol/l. The ratios between plasma 5-S-CD and tumour volume were found to be significantly lower in the INF-β treated mice than in the control mice. These results Indicate that plasma 5-S-CD is useful in evaluating the efficacy of Immuno- and chemotherapeutlc agents in experimental melanomas.
